Teladoc Health (NYSE:TDOC) Price Target Raised to $12.00 at Barclays

Teladoc Health (NYSE:TDOC) had its price target hoisted by stock analysts at Barclays from $10.00 to $12.00 in a research report issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the health services provider’s stock. Barclays‘s target price points to a potential upside of 31.58% from the stock’s previous close.

Several other research analysts also recently weighed in on the stock. Truist Financial decreased their target price on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating for the company in a research note on Friday, August 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 target price on shares of Teladoc Health in a research note on Tuesday, August 20th. JPMorgan Chase & Co. decreased their target price on shares of Teladoc Health from $16.00 to $9.00 and set a “neutral” rating for the company in a research note on Monday, August 26th. Oppenheimer decreased their target price on shares of Teladoc Health from $21.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. Finally, Deutsche Bank Aktiengesellschaft cut their price target on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating on the stock in a report on Friday, August 2nd. Fourteen research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $11.86.

Teladoc Health Trading Up 2.9 %

TDOC traded up $0.26 during trading on Thursday, hitting $9.12. 10,399,774 shares of the company’s stock were exchanged, compared to its average volume of 5,452,342. The company has a current ratio of 1.66, a quick ratio of 1.62 and a debt-to-equity ratio of 0.66. Teladoc Health has a 1 year low of $6.76 and a 1 year high of $22.54. The stock has a 50 day moving average price of $8.41 and a 200 day moving average price of $9.72. The firm has a market cap of $1.56 billion, a P/E ratio of -6.44 and a beta of 0.91.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.10. Teladoc Health had a negative net margin of 38.54% and a negative return on equity of 10.25%. The company had revenue of $640.51 million during the quarter, compared to the consensus estimate of $630.50 million. As a group, analysts expect that Teladoc Health will post -1.18 EPS for the current fiscal year.

Insider Activity at Teladoc Health

In other news, CFO Mala Murthy sold 8,750 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total transaction of $62,650.00. Following the completion of the transaction, the chief financial officer now owns 85,767 shares in the company, valued at approximately $614,091.72. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CFO Mala Murthy sold 8,750 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total value of $62,650.00. Following the completion of the sale, the chief financial officer now directly owns 85,767 shares of the company’s stock, valued at $614,091.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas Mckinley acquired 4,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average cost of $7.69 per share, for a total transaction of $30,760.00. Following the transaction, the director now owns 39,077 shares of the company’s stock, valued at approximately $300,502.13. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 57,377 shares of company stock worth $438,054 in the last 90 days. Corporate insiders own 0.95% of the company’s stock.

Institutional Trading of Teladoc Health

A number of institutional investors and hedge funds have recently modified their holdings of TDOC. Signaturefd LLC increased its position in Teladoc Health by 148.7% during the second quarter. Signaturefd LLC now owns 2,868 shares of the health services provider’s stock worth $28,000 after acquiring an additional 1,715 shares during the period. International Assets Investment Management LLC bought a new position in Teladoc Health during the second quarter worth $29,000. Blue Trust Inc. increased its position in Teladoc Health by 84.5% during the third quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider’s stock worth $40,000 after acquiring an additional 1,854 shares during the period. Doheny Asset Management CA bought a new position in Teladoc Health during the second quarter worth $46,000. Finally, SageView Advisory Group LLC bought a new position in Teladoc Health during the first quarter worth $48,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.